Rating: Good. The thesis is a lower-entry cash-secured put on Pfizer, supported by raised full-year guidance and a stock price above its recent moving averages. It is not Great because the bid/ask spread consumes a meaningful share of the credit, and earnings-call, drug-development and dividend…
Included with YieldCove PRO
This area is part of a YieldCove PRO membership. Members find it unlocked here as soon as they sign in.
Unlock this tip
This premium wheel tip is included with YieldCove PRO.
Already have an account? Sign in
Rather learn it with a person? 1:1 coaching with Eddie starts at $89/month, PRO included. Explore coaching
Secure checkout via Stripe · Cancel anytime
- Your tracker stays free
- Billing handled by Stripe
- Manage or cancel in Settings → Billing
Not ready to subscribe? Browse the free market news



